RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
Go back to RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease| REDHILL BIO SP ADS (NASDAQ: RDHL) | Delayed: 0.60 +0.05 (9.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.55 | 52 Week High | $16.54 | |||
| Open | $0.57 | 52 Week Low | $8.10 | |||
| Day High | $0.60 | P/E | N/A | |||
| Day Low | $0.57 | EPS | $0.00 | |||
| Volume | 206,663 | |||||
| REDHILL BIO SP ADS (NASDAQ: RDHL) | Delayed: 0.60 +0.05 (9.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.55 | 52 Week High | $16.54 | |||
| Open | $0.57 | 52 Week Low | $8.10 | |||
| Day High | $0.60 | P/E | N/A | |||
| Day Low | $0.57 | EPS | $0.00 | |||
| Volume | 206,663 | |||||
